A New Paradigm in Oncology:
From Treatment to Prevention
CrisPRO.ai is the world's first AI-powered platform designed not just to fight cancer, but to proactively prevent its deadliest outcome: metastasis. We are turning the tide on cancer by making metastatic prevention a clinical reality.
The True Enemy: Preventing Metastasis
The Problem: Over 90% of cancer-related deaths are not caused by the primary tumor, but by metastasis—the process by which cancer spreads to other parts of the body. The current medical paradigm is reactive, treating metastasis only after it's clinically detectable. We are missing the critical window to prevent it.
Our Solution: A strategic transformation from a simple research tool to the world's first AI-powered metastasis prevention system. We don't just provide data; we provide a predictive, proactive, and personalized strategy to stop metastasis before it starts.
of cancer deaths caused by metastasis, not primary tumors
cancer deaths annually in US - most preventable
current solutions for metastasis prevention
Introducing: The Metastatic Potential Report
Instead of simple mutation lists, our platform generates a comprehensive, actionable report that provides oncologists with a roadmap to prevention. This is our core, revolutionary output.
Metastatic Risk Score
Stage-by-Stage Breakdown
Key Genetic Drivers
Prioritized Strategies
Pre-Designed Interventions
💡 Interactive Demo: Hover over each component above to see how our Metastatic Potential Report transforms cancer care from reactive to preventive.
The Patient's Broken Journey
Today's cancer care is reactive, fragmented, and often too late. We're building a proactive, integrated system that prevents metastasis before it starts.
The Old Way: Reactive & Fragmented
Treatment after the damage is done
Genetic Testing
Patient receives genetic test results filled with Variants of Unknown Significance (VUS).
Key Problems:
- 40-60% of results are VUS - clinically unusable
- Months of waiting for unclear results
- No actionable treatment guidance
Clinical Confusion
Oncologist struggles to interpret ambiguous genetic data and make treatment decisions.
Key Problems:
- Physicians spend 49% of time on administrative tasks
- Limited genomic expertise in most practices
- Treatment decisions based on incomplete information
Trial & Error Treatment
Patient undergoes standard-of-care treatments that may not match their genetic profile.
Key Problems:
- Average 3-4 treatment attempts before finding effective therapy
- Precious time lost during cancer progression
- Unnecessary toxicity from ineffective treatments
Metastatic Progression
Without precision targeting, cancer metastasizes and becomes increasingly difficult to treat.
Key Problems:
- 90% of cancer deaths are from metastasis
- Limited treatment options once cancer spreads
- Exponentially higher treatment costs
The CrisPRO Way: Proactive & Integrated
Prevention before progression
Instant VUS Resolution
CrisPRO's Zeta Oracle immediately converts VUS into definitive, actionable insights.
CrisPRO Solutions:
- Physics-based analysis provides definitive answers
- Real-time results within minutes
- Clear therapeutic recommendations
Metastatic Risk Assessment
Our 8-step framework predicts metastatic potential and identifies intervention points.
CrisPRO Solutions:
- Comprehensive metastatic pathway analysis
- Stage-by-stage risk breakdown
- Prioritized intervention strategies
Precision Therapeutics
Zeta Forge designs personalized CRISPR interventions targeting patient-specific vulnerabilities.
CrisPRO Solutions:
- Custom-designed therapeutic strategies
- Pre-validated in digital twins
- Optimal timing and dosing protocols
Proactive Prevention
Treatment begins before metastasis occurs, dramatically improving outcomes.
CrisPRO Solutions:
- Prevention-focused rather than reactive
- Continuous monitoring and adaptation
- Significantly improved survival rates
The Transformation
Cancer deaths from metastasis
Before metastasis occurs
Our Solution: The Pillars of Innovation
Our CrisPRO Oncology Co-Pilot is not a single tool, but a holistic ecosystem built on interconnected strategic pillars. This is our blueprint for victory.
Pillar 1: Information Dominance
Ingest and synthesize all patient data into a unified "Digital Twin" foundation.
Pillar 2: First-Principles Analysis
Annihilate VUS and provide deep biological context for every prediction.
Pillar 3: The Zeta Forge
Design, validate, and de-risk novel therapeutics `in silico`, compressing R&D.
Pillar 4: Predictive Digital Twins
Simulate tumor evolution and therapy response to identify resistance pathways early.
Pillar 5: AI-Orchestrated Logistics
Automate clinical operations and match patients to trials based on biological intent.
Pillar 6: The Triumvirate Checkpoint
An internal, automated validation system to ensure every output is not just powerful, but perfect.
Go-to-Market Strategy: A Multi-Front War
Pharma & Biotech
Lead with our Pre-Clinical Simulation Engine to de-risk their R&D pipeline and solve their >$2B per-drug failure problem.
Health Systems
Lead with our VUS Annihilation capability to provide immediate, undeniable clinical value and close their actionability gap.
Integrations
Embedding our platform as a 'premium intelligence layer' into EMRs and diagnostics.
DeSci & Web3
Pioneer IP-NFTs to raise non-dilutive R&D capital from Bio-DAOs and the Web3 community, creating a new funding paradigm.
5.0 A New Economic Engine: DeSci & Verification
We're not just building better therapeutics—we're creating an entirely new funding and verification paradigm that transforms how biotech innovation is financed and validated globally.
Traditional Funding Timeline
18-24 months
DeSci Funding Timeline
2-4 weeks
IP Liquidity Increase
10,000x
Global Investor Access
24/7
Step 1: IP-NFT Creation
We tokenize our therapeutic designs as IP-NFTs, creating liquid, tradeable intellectual property assets backed by real scientific value.
Step 2: Bio-DAO Partnerships
We partner with decentralized autonomous organizations focused on specific disease areas, leveraging their community and capital.
Step 3: Verification Layer
Our AI-powered verification system ensures the integrity and reproducibility of all research outputs, creating trust in the ecosystem.
Step 4: Global Liquidity
We create the world's first liquid market for biotech IP, enabling real-time price discovery and efficient capital allocation.
The DeSci Advantage
Why traditional biotech funding is broken and how we fix it
Traditional Problems:
- 18-24 month funding cycles
- Illiquid IP assets
- Limited investor access
- Opaque research processes
CrisPRO Solutions:
- 2-4 week tokenized funding
- 24/7 liquid IP markets
- Global investor participation
- AI-verified research integrity
The 8-Step Metastasis Framework: Our Clinical Roadmap
Our platform directly maps its analytical and generative capabilities to each critical step of cancer metastasis, providing a comprehensive, stage-by-stage intervention strategy.
Primary Tumor Growth
Driver mutation identification & essentiality scoring
Angiogenesis
VEGF pathway disruption strategies
EMT
Cell adhesion restoration & mobility prevention
Invasion
MMP enzyme knockout strategies
Circulation Survival
Immune visibility restoration
Homing
Receptor blinding strategies
Extravasation
Organ-specific targeting prevention
Dormancy Control
Forced hibernation induction
Interactive Framework: Click on any step above to explore detailed intervention strategies. This framework leverages our core endpoints to create a cohesive, actionable plan for metastasis prevention.
4.0 Business Model: Monetizing Metastatic Prevention
Our business model is designed to integrate seamlessly into the clinical oncology workflow, capturing value by providing an indispensable, first-of-its-kind decision support tool.
Oncology Market
Global oncology market size in 2023, growing at 7.5% CAGR
Precision Medicine
Precision medicine market, our direct addressable market
Cancer Diagnostics
Cancer diagnostics market, our immediate opportunity
Interactive Revenue Calculator
Clinical Decision Support
Per-report fee for Metastatic Potential Reports
Target: Oncologists, Cancer Centers, Hospital Networks
Pharmaceutical Partnerships
API access and custom analysis for drug development
Target: Biotech & Pharmaceutical R&D Departments
Revenue Projection Summary
Projected Monthly Revenue
$75,000
Based on sliders above
Projected Annual Revenue
$900,000
12-month run rate
5-Year Potential
$11,250,000
Factoring in growth
5.0 Team: The Architects of Biological Innovation
Our founding team combines world-class expertise in CRISPR technology, AI/ML, and biotech commercialization. We are the rare team that can both envision and execute the future of precision medicine.
Fahad Kiani
Chief Technical and Executive Officer & Co-Founder
6 years experience
Fahad is a seasoned entrepreneur with a passion for using technology to improve healthcare. He is the co-founder of Jedilabs.org, a non-profit organization dedicated to advancing AI and ML in healthcare. Previosuly was a Senior Solutions Engineer at Talend, supporting enterprise customers around data integration and data governance. Led successful exits of 1stDibs and iMedicare as a founding team member.
Rahima Nayeem
Chief Clinical Officer & Co-Founder
8 years experience
Dr. Rahima Nayeem is an internist in New York and is affiliated with North Shore University Hospital at Northwell Health. She received her medical degree from State University of New York Downstate Medical Center College of Medicine and has been in practice between 6-10 years
8.0 The Call to Action
The oncology market is not a space for incremental improvement. The multi-trillion-dollar opportunity lies in providing definitive solutions. CrisPRO.ai is the only company with the technology, strategy, and vision to do so.